Celaid Therapeutics is a Japan-based biotechnology company, which has developed a platform technology to efficiently expand hematopoietic stem cells ex vivo without choosing its origins, including bone marrow, cord blood, or peripheral blood. By using the novel technology, we are developing a cell therapy product that brings HSC transplantation to the next level and helps patients with blood disorders. Our technology has many potential applications including gene/cell therapy that utilize gene editing on HSC.
Our mission is to improve QOL of patients, their families, and HSC donors all over the world.
Our mission is to improve QOL of patients, their families, and HSC donors all over the world.
Location: Japan
Employees: 11-50
Total raised: $7.16M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 30.06.2021 | The Univer... | ut-ec.co.j... |
| 11.10.2024 | Kobe Unive... | kuc.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.10.2025 | Series B | $7.16M | Osaka Univ... |
Mentions in press and media 11
| Date | Title | Description |
| 07.10.2025 | Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing | TOKYO, Oct. 7, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid"), today announced the successful completion of the 1st Close of its Series B financing round, raising JPY 1.055 billion (USD 7.2 million) from venture capital ... |
| 28.08.2025 | Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs | TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HS... |
| 08.05.2024 | Cereide Therapeutics, which researches and develops cell therapy and gene therapy products using hematopoietic stem cells, has completed raising a total of 1.2 billion yen worth of Series A funding. | - |
| 08.05.2024 | Cereide Therapeutics, which researches and develops cell therapy and gene therapy products using hematopoietic stem cells, has completed raising a total of 1.2 billion yen worth of Series A funding. | Cereide Therapeutics, which researches and develops cell therapy and gene therapy products using hematopoietic stem cells, has completed raising a total of 1.2 billion yen worth of Series A funding. *View in browser* *Celeide Therapeutics C... |
| 28.03.2024 | Kobe Medical Industrial City Promotion Organization and Celide Therapeutics sign a joint research agreement to develop vascular regeneration products using in vitro expanded human hematopoietic stem c... | - |
| 28.03.2024 | Kobe Medical Industrial City Promotion Organization and Celide Therapeutics sign a joint research agreement to develop vascular regeneration products using in vitro expanded human hematopoietic stem c... | Kobe Medical Industrial City Promotion Organization and Celide Therapeutics sign a joint research agreement to develop vascular regeneration products using in vitro expanded human hematopoietic stem cells *View in browser* *Celeide Therapeu... |
| 22.03.2024 | Ceride Therapeutics Co., Ltd. selected for NEDO’s Deep Tech Startup Support Project (DTSU) | - |
| 22.03.2024 | Ceride Therapeutics Co., Ltd. selected for NEDO’s Deep Tech Startup Support Project (DTSU) | Ceride Therapeutics Co., Ltd. selected for NEDO’s Deep Tech Startup Support Project (DTSU) *View in browser* *Celeide Therapeutics Co., Ltd.* Press release: March 22, 2024 ** Ceride Therapeutics Co., Ltd. selected for NEDO’s Deep Tech Start... |
| 14.12.2023 | C4U and Celide Therapeutics sign joint research agreement to realize hematopoietic stem cell gene therapy products | Ceride Therapeutics Co., Ltd. C4U and Celide Therapeutics sign joint research agreement to realize hematopoietic stem cell gene therapy products …… C4U Co., Ltd. (Headquarters: Suita City, Osaka Prefecture, Representative Director: Akimitsu... |
| 14.12.2023 | C4U and Celide Therapeutics sign joint research agreement to realize hematopoietic stem cell gene therapy products | - |
Show more